- Supported exchanges /
- CO /
- PEG.CO
Pharma Equity Group A/S Cl A (PEG CO) stock market data APIs
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma. The company was incorporated in 2002 and is based in Hørsholm, Denmark.
Pharma Equity Group A/S Cl A Financial Data Overview
| 0.397 | |
| 0.4515 | |
| - | |
| 0.5215 | |
| -0.203 | |
| 0.15-0.496 | |
| 193 M | |
| 1 228 M | |
| 0 | |
| -0.01 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Pharma Equity Group A/S Cl A Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -28 919 000
- Earnings Per Share -0.03
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Pharma Equity Group A/S Cl A Earnings via APIs
- Latest Release 2024-06-30
- EPS/Forecast 0
Get Pharma Equity Group A/S Cl A End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
